![JMA – Ninja & Deep Jandu [Official MV] Kaptaan](https://i.ytimg.com/vi/-dsfIh319s0/maxresdefault.jpg "JMA – Ninja & Deep Jandu [Official MV] Kaptaan")
On the sidelines of a programme right here, AAICLAS Chief Working Officer Ok Selvakumar informed reporters right here, “Within the first part, two crore doses of COVID-19 vaccine are to be delivered from Pune to 41 locations throughout the nation with the assistance of greater than 100 flights.” This supply is deliberate from January 6 to January 8.
Selvakumar was in Indore to attend the inauguration ceremony of a brand new worldwide air cargo terminal at Devi Ahilya Bai Holkar Airport. The terminal has been constructed by AAICLAS, a subsidiary of the Airports Authority of India, at a value of Rs 2.26 crore.
Selvakumar stated a complete of 9 lakh doses of the vaccine are deliberate to be delivered in 4 huge cities of Madhya Pradesh — Indore, Bhopal, Jabalpur and Gwalior — within the first part.
With out specifying the locations, Selvakumar stated the preparations can be made on the respective airports for the supply in such a manner that the vaccines have been loaded into the vans inside seven minutes, protecting the chilly chain intact.
Speaking about COVID-19 vaccine distribution plan, he stated over 100 flights can be operated to ship the vaccines throughout the nation and every plane can be loaded with 1,800 kg of vaccines.
Selvakumar stated, “The vaccine will probably be saved in a particular gel packing to keep up the set temperature. This gel will preserve correct temperature for twenty-four hours.”
The vaccine will have to be administered to the particular person involved inside 24 hours of being packed.
He stated, “The gap between Kashmir to Kanyakumari will be coated by air in 4 hours.”
There will probably be coordination between completely different authorities departments for vaccination. So, there will probably be no drawback in getting the vaccine administered inside the timeframe.
On Sunday, Drug Controller Basic of India (DCGI) accepted Covishield of Serum Institute of India (SII) and Bharat Biotech’s Covaxin for restricted emergency use.
